// App-Quantinova.ai

: THE XPO1 INHIBITOR KPT-8602 WORKS SYNERGISTIC WITH DEXAMETHASONE TO INHIBIT ACUTE LYMPHOBLASTIC LEUKEMIA CELLS

Researchers

Presenter

  • Delphine Verbeke

Principal Investigators

  • Charles de Bock

  • Sofie Demeyer

  • Cristina Prieto

  • Jolien De Bie

  • Olga Gielen

  • Nicole Mentens

  • Dirk Daelemans

  • Anne Uyttebroeck

  • Nancy Boeckx

  • Kim De Keersmaecker

  • Johan maertens

  • Heidi Segers

  • Jan Cools

Medical Centers

  • Center for Human Genetics, LKI,KU Leuven,Leuven,Belgium;Center for Cancer Biology,VIB,Leuven,Belgium

  • Children's Cancer Institute, Sydney, Australia

  • Center for Human Genetics, LKI,KU Leuven,Leuven,Belgium;Center for Cancer Biology,VIB,Leuven,Belgium

  • Center for Human Genetics, LKI,KU Leuven,Leuven,Belgium;Center for Cancer Biology,VIB,Leuven,Belgium

  • KU Leuven, Leuven, Belgium

  • Rega Institute, KU Leuven, Leuven, Belgium

  • Department of Imaging & Pathology, KU Leuven, Leuven, Belgium

  • Department of Imaging & Pathology, KU Leuven, Leuven, Belgium

  • Belta-TBNet and Department of Microbiology, Immunology and Transplantation, KU leuven, Leuven, Belgium

Locations

  • Belgium

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of differentiation 45

  • Exportin 1

Drug/Treatment

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Vincristine

  • Doxorubicin

  • KPT-8602

  • DMSO

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved